Virology, pathophysiology and neuroinvasion mechanisms of SARS-CoV-2: A mini literature review

Arash Pourgholaminejad¹, Samaneh Kazemi², Alia Saberi³

¹ Department of Immunology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
² Deputy of Research and Technology, Guilan University of Medical Sciences, Rasht, Iran
³ Department of Neurology, Poursina Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

ABSTRACT

Coronavirus-2 (CoV-2) is known as a respiratory pathogen for which the accumulation of evidence suggest that the severe acute respiratory syndrome (SARS) can cause critical pathologies in vulnerable patients. The coronavirus disease-2019 (COVID-19) pandemic is an example of a multi-systemic infectious disease. In addition of respiratory manifestations and severe pneumonia related to COVID-19, The SARS-CoV-2 can penetrate into the central nervous system (CNS) and participate in the induction of neurological disorders and promote some neuropathies. Knowledge of the spectrum of SARS-CoV-2-associated pathophysiology and neuroinvasion pathways will lead to improved clinical outcomes and better treatment algorithms. The aim of this review is to summarize available knowledge on the identification of virology, neuroinvasion mechanisms and the pathophysiology of SARS-CoV-2 in the CNS.

Keywords: SARS-CoV-2, central nervous system, pathophysiology

INTRODUCTION

Several cases of unknown origin pneumonia were detected in Wuhan, Hubei province of China in December 2019 and a new zoonotic-origin coronavirus named 2019 novel coronavirus (2019-nCoV) was isolated in January 2020 [1,2]. On March 11, 2020 the World Health Organization (WHO) declared the COVID-19 pandemic and among 167 million total cases worldwide, more than 3.48 million people have died from critical COVID-19 until now (May-27, 2021) [3,4].

There are records of a number of mild to serious neurological syndromes in SARS-CoV-2 infected patients, including headache, anosmia, seizures, coma, encephalitis, guillain-barre syndrome, and acute cerebrovascular incidents (ischemic stroke, intracerebral hemorrhage and cerebral venous sinus thrombosis) [5]. Early reports from China indicated that up to 36% of COVID-19 patients may experience neurological manifestations [6]. Although, in this review we will report the relationship between COVID-19 and the nervous system. Accordingly, mechanisms associated to neuroinvasion and pathogenesis of SARS-CoV-2 infection will be discussed.

VIROLOGY OF SARS-COV-2

Based on clinical manifestations, blood testing, and chest radiographs, the COVID-19 was diagnosed as virus-induced pneumonia [7]. SARS-CoV-2 was regarded as a member of the β-CoVs after sequence and evolutionary tree analysis. The CoVs family is a class of single-stranded, positive-sense enveloped RNA viruses with a wide range of natural roots. Respiratory, gastrointestinal, hepatic and neurological disorders may be caused by these virus families. According to genotype and serology, the CoVs families are classified into four subgroups: α-, β-, γ- and δ-CoVs. Infections of human CoV are caused by α- and β-CoVs. SARS-CoV and MERS-CoV are members of β-CoVs. Genome-wide phylogenetic analysis indi-
cates that SARS-CoV-2 shares 79.5% and 50% se-
quence identity to SARS and MERS coronaviruses,
respectively [8].

PATHOPHYSIOLOGY OF NEUROLOGICAL DAMAGES
RELATED TO COVID-19

Direct viral injury

In nervous system tissue samples (such as cere-
brospinal fluid or brain), the genetic material and
even proteins of different viruses can also be found,
indicating that viruses can enter the nervous sys-
tem directly and cause nerve damage [9,10]. The
cerebral vessels come into close contact with virus-
es and are influenced by viral infection and system-
ic inflammatory changes [11]. There is currently no
conclusive evidence that coronaviruses cause in-
flammatory neuromuscular diseases through direct
invasion of peripheral nerves or muscles or through
molecular mimicry. The majority of COVID-19 pa-
tients’ neurologic symptoms tend to be indirect and
as a consequence of bystander neuron damage [12].

Cytokine storm

The cytokine storm could play an important role
in the immunopathology of COVID-19, as in a seri-
ous influenza infection [13]. In COVID-19 patients,
pro-inflammatory cytokines and chemokines in-
cluding tumor necrosis factor (TNF)-α, interleukin
1β (IL-1β), IL-6, granulocyte colony stimulating fac-
tor, interferon gamma-induced protein-10, mono-
cyte chemo-attractant protein-1 (MCP-1), and mac-
rophage inflammatory protein 1-α have been
shown to be significantly elevated [14,15]. In addi-
tion, in critical form of COVID-19, lymphopenia in
both CD4+ helper T cells and CD8+ cytotoxic T cells,
as well as high production of IL-6 and IL-10 was
seen [16]. The permeability of the blood–brain bar-
rier (BBB) is increased after the emergence of hy-
per-inflammation during the cytokine storm. Then
CD68+ monocyte/macrophages and CD3+ T cells mi-
grate into the infected brain and a large number of
inflammatory cytokines are released, which pro-
motes thrombosis and stroke [17,18]. Viral sepsis is
induced by disseminated COVID-19’s direct assault
on various tissues, immunological pathogenesis
mediated by systemic cytokine storms, and micro-
circulation dysfunction [13].

Unintended host immunity and systematic disease
effects

Infectious diseases, primarily by molecular
mimicry, have long been seen as one of the causes
for autoimmune and auto-inflammatory diseases.
The number of complications following SARS-CoV-2
infection in adults is wider than in children and in-
volves autoimmune disorders, but their occurrence
is too rare for adults [19]. Emerging reports indicate
that infection with SARS-CoV-2 can lead to autoim-
mune and auto-inflammatory diseases in children,
such as pediatric multi-systemic inflammatory syn-
drome (PIMS; including Kawasaki-like disease,
Kawasaki disease shock syndrome, toxic shock syn-
drome, myocarditis, and macrophage activation
syndrome) [20-25].

Systematic disease effects

A systemic disease is a disease that affects the
body as a whole, or affects a variety of organs and
tissues [26]. Several experiments have been carried
out in order to better understand this disease’s
pathogenesis and clinical aspects. It seems that due
to the direct impact of the virus and its triggered
widespread inflammatory response, SARS-CoV-2 af-
facts almost all body organs including respiratory
system, cardiovascular system, urinary system, he-
matopoietic system, gastrointestinal tract system
plus hepatic and pancreatic involvement, and nerv-
ous system [22].

NEUROINVASION MECHANISMS

Trans-synaptic spread

There is growing evidence of the invasion of pe-
риpheral nerve terminals by human and non-hu-
man CoV, retrograde spread through nerve synap-
es, and access to the CNS [23,27]. Retrograde
trans-synaptic spread with either endocytosis or
exocytosis and quick axonal transport of vesicles
along the microtubules are proposed mechanisms
for moving coronaviruses [7]. Studies using a varie-
ty of tracing molecules have shown strong transsyn-
aptic marking after intracellular injection, implying
that interneuronal transfer occurs at synaptic junc-
tions. However, the transsynaptic mechanism is
complex and difficult to research, in part due to the
synapse’s small yet complex structure and the lack
of reliable tracing methods [28]. The transsynaptic
exchanges of coronaviruses can be facilitated by
membranous coating-mediated endo/exocytosis, ac-
cording to Li et al. They also speculated that the
transsynaptic pathway may be modified to work
with larger granular materials like viruses [28].

Olfactory nerve

A common cause of olfactory dysfunction is viral
upper respiratory tract infection, in part because
the olfactory epithelium is situated adjacent to the
respiratory epithelium, the site of replication of se-
vral viruses that cause upper respiratory tract infec-
tion, and that the environment is directly accessible
to olfactory neurons. The increasing amount of in-
Internet searches that inquire about smell loss is closely associated with the increased prevalence of COVID-19 [29]. Therefore, another possible mechanism for SARS-CoV-2 entry to the CNS is direct entry through the olfactory nerve [7]. Olfactory and gustatory functional dysfunction has been identified as being a COVID-19 characteristic and may be a significant clinical outcome indicator [30].

**Blood-brain barrier spread**

By passing through vascular endothelial cells (all endothelial cells express ACE-2) or by passing virus infected leukocytes through the BBB, SARS-CoV-2 may invade the CNS [7]. Both mechanisms are described below.

*Connection to angiotensin-converting enzyme 2 (ACE2)*

The presence of ACE-2 receptors is now understood to be important for the cellular entry of extreme SARS-CoV-2. On the viral surface, the spike proteins bind to the host cells with the ACE-2 receptor and enter the cells [31]. Viral cellular tropism is determined by the presence of ACE-2 on tissues. In humans, ACE-2 receptors, are expressed in several tissues such as the airway epithelium, lung parenchyma, renal cells, small intestine, vascular endothelium, and CNS [32].

SARS-CoV-2 and its structure have clear similarities to other coronavirus species which discovered until now, and the identified SARS-CoV-2 genome sequence closely resembles other beta-coronaviruses including SARS-CoV-1 [33,34]. SARS-CoV-1 and SARS-CoV-2 using the same ACE2 receptor for cell entry [33,35], while SARS-CoV-2 has a higher binding affinity for ACE2 than SARS-CoV-1, this could explain why SARS-CoV-2 is more transmissible [36]. ACE2 binds to SARS-CoV-2 with an affinity of 15 nM, approximately 10-20-times higher than that of SARS-CoV-1, and this might clarify its greater virulence [37]. Cell entry also requires priming of the S protein by the cellular serine protease TMPRSS2 or other proteases, which results in S protein cleavage at the S1/S2 and S2’ sites, allowing the fusion of viral and cellular membranes, a process guided by the S2 subunit. The co-expression of ACE2 and TMPRSS2 is needed to complete this entry procedure. Most of the amino acid residues needed for SARS-S protein binding to ACE2 was conserved in SARS-2-S protein, according to an analysis of the receptor binding motif (RBM), a portion of the RBD that connects with ACE2 [19].

**Through infected leukocytes**

Increased blood-brain barrier permeability caused by systemic inflammation in the COVID-19 infection could allow infected immune cells to pass through the CNS and thus to enter the virus [38]. Patients infected with SARS-CoV-2 that develop cerebrovascular disease often develop complications such as hypertension and other stroke risk factors. Pro-inflammatory modifications during SARS-CoV-2 infection are linked to stroke risk factors, and leukocyte activation and subsequent cerebrovascular thrombosis have been observed in response to inflammatory stimulation. BBB disruption is caused by the aggregation of inflammatory immune cells in the vascular wall, which can lead to thrombosis and increase the risk of stroke [17].

**Vascular endothelium**

Not only lung tissue, but also vascular endothelium is the target of SARS-CoV-2 because vascular endothelium has ACE2, like lung tissue. There are several roles in the vascular endothelium and it is the only place where the von Willebrand factor (VWF) is processed. During its infection, SARS-CoV-2 also induces thrombosis attacks. Angiotensin II levels are elevated by blocking of ACE2 by SARS-CoV-2. In both the vascular endothelium and platelets, angiotensin II stimulation and local stimuli such as H+ ion and hypoxia activate Na+/H+ exchanger (NHE). By inducing NHE activation, SARS-CoV-2 can lead to thrombosis [39]. The high affinity of SARS-CoV-2 to the ACE2 receptor and probably other receptors still to be identified could lead to severe renin-angiotensin-aldosterone system (RAAS) dysfunction, as ACE2 is a key counter-regulator in this pathway. ACE2 cleaves angiotensin II into angiotensin I, which has vasodilator, antiproliferative, and antifibrotic effects [40]. At least partly, the organotropism of SARS-CoV-2 may be clarified by the hypothesis that the virus uses RAAS as a vehicle for its volatile early assault on human cells [41].

**CONCLUSIONS**

Awareness of the spectrum of pathophysiology and neuroinvasion mechanisms associated with SARS-CoV-2 will lead to improved clinical results and better algorithms for treatment. As regards, the SARS-CoV-2 pandemic is an example of a multi-systemic infectious disease.
REFERENCES

1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He XY, Liang WJ, Ren L, Chen B, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720.

2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Wang X, Si H, Zhu Y, Li B, Huang CL, Chen HM. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270-273.

3. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, Liao P, Qiu JF, Lin Y, Cai XF, Wang DQ. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020 Jun;26(6):845-848.

4. Coronavirus disease (COVID-19). 2020; Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.

5. Frontera J, Mainail S, Fink EL, Robertson CL, et al. Global consortium study of neurological disease in COVID-19 (GCS-NeuroCOVID): study design and rationale. Neurol Care. 2020 Aug;33:25-34.

6. Mao L, Jin H, Wang M, Hu Y, Chen S, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. AMA Neurol. 2020 Jun;177(3):683-90.

7. Huang C, Wang Y, Li X, Zhao J, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506.

8. Jin Y, Yang H, Li W, Wu W, Chen S, Zhang W, Duan G. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020 Apr;12(4):372.

9. Dubé M, Le Copanec A, Wong AH, Rini JM, Desforges M, Talbot PJ. Axonal transport enables neuron-to-neuron propagation of human coronavirus OC43. J Virol. 2018 Sep 1;92(17):e00404-18.

10. Arbour N, Day R, Newcombe J, Talbot PJ. Neuroinvasion by human respiratory coronaviruses. J Virol. 2000 Oct 1;74(19):8913-8921.

11. Pugin D, Vargas MI, Thieffry C, Schibler M, et al. COVID-19-related encephalopathy responsive to high-dose glucocorticoids. Neurology. 2020 Sep 22;95(12):543-546.

12. Aziz SA. Neurological injuries in COVID-19 patients: direct viral invasion or a bystander injury after infection of epithelial/endothelial cells. J Neurol. 2020;26(5):631-641.

13. Zubaar AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol. 2020 Aug 1;77(8):1018-1027.

14. Klopfenstein T, Kadiane-Oussou NJ, Toko L, Royer PY, Lepiller Q, Gendrin V, Zayet S. Features of anosmia in COVID-19. Med Mal Infect. 2020 Apr;12(4):372.

15. Paolo G. Does COVID-19 cause permanent damage to olfactory and gustatory function?. Med Hypotheses. 2020 Oct 1;143:110086.

16. Wan S, Yi Q, Fan S, Liu J, Zhang X, Guo I, Lang C, Xiao Q, Xiao K, Yi Z, Qiang M. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). MedRxiv. 2020 Jan 1.

17. Fan H, Tang X, Song Y, Liu P, Chen Y. Influence of COVID-19 on Cerebrovascular Disease and its Possible Mechanism. Neuropsychiatr Dis Treat. 2020;16:1359-1367.

18. Fugate JE, Lyons JL, Thakur KT, Smith BR, Hedley-Whyte ET, Mateen FJ. Infectious causes of stroke. Lancet Infect Dis. 2014 Sep 1;14(9):869-8680.

19. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8.

20. Zipre KG, Dixit S, Kulkarni AP, Sapra H, et al. Pathophysiological Mechanisms and Neurological Manifestations in COVID-19. Indian J Crit Care Med. 2020 Oct;24(10):975-980.

21. Spiegel M, Schneider K, Weber F, Weidmann M, Hufert FT. Interaction of severe acute respiratory syndrome-associated coronavirus with dendritic cells. J Gen Virol. 2006 Jul;87(7):1953-1960.

22. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Liu C, Yang C. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020 Jul 1;87:18-22.

23. Cure E, Cure MC. COVID-19 May Predispose to Thrombosis by Affecting Both Vascular Endothelium and Platelets. Clin Appl Thromb Hemost. 2020 Jul 3;26:1076029620933945.

24. Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):1653-1659.

25. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endotheliitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020 Jul 9;383(2):120-128.

26. Koyuncu O, Hogue J. Virus infections in the nervous system. Cell Host Microbe. 2013 Apr 17;13(4):379-393.

27. Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, Su X, Cao B. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020 May 9;395(10235):1517-1520.

28. Li YC, Bai WZ, HiranO N, Hayashida T, et al. Neurotropic virus tracing suggests a membranous-coating-mediated mechanism for transsynaptic communication. J Comp Neurol. 2013 Jan 1;521(1):203-212.

29. Liu J, Li S, Liu J, Liang B, Wang X, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EbioMedicine. 2020 May 1;55:102763.

30. Galeotti C, Bayn J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol. 2020 Aug;16(8):413-414.

31. Verdini I, Mazza A, Gervasoni A, Martellii L, Ruggieri M, Ciuffreda M, Bonamoni E, D’Antiga L. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020 Jun 6;395(10239):1771-1778.

32. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020 May 23;395(10237):1607-1608.

33. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270-273.

34. Ather A, Patel B, Ruparel NB, Diogenes A, Hargreaves KM. Coronavirus disease 19 (COVID-19): implications for clinical dental care. J Endod. 2020 May 1;46(5):584-595.

35. Ge XY, Li JL, Yang XL, Chmura AA, Zhu G, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013 Nov;503(7477):535-538.

36. Wang Q, Zhang Y, Wu L, Niu S, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020 May 14;181(4):894-904.

37. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020 Mar 13;367(6483):1260-1263.

38. Belhadjer Z, Miet M, Bajolle F, Khraiche D, et al. Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic. Circulation. 2020 Aug 4;142(5):429-436.

39. Rapid risk assessment: Paediatric inflammatory multisystem syndrome and SARS-CoV-2 in children. Available at: https://www.ecdc.europa.eu/en/publications-data/paediatric-inflammatory-multisystem-syndrome-and-sars-cov-2-rapid-risk-assessment.

40. Blumfield E, Levin TL, Kuriyan J, Lee EY, Liszewski MC. Imaging findings in multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease (COVID-19). American Journal of Roentgenology. 2021 Feb 29;216(2):S07-S17.

41. Dorland WAN. Dorland’s Illustrated Medical Dictionary. 28th ed. San Diego, California: Harcourt Brace & Company, 1994.